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Abstract: Diabetes mellitus is an internationally recognized health problem and a 
leading cause of death worldwide. However, the most significant increase in 
prevalence is expected to occur in Asia and Africa, where most patients will be found 
by 2030. Diabetic Mellitus is a clinical and metabolic syndrome characterized by 
abnormal carbohydrate, protein, and fat metabolism resulting in hyperglycemia, 
increased protein breakdown, Ketosis or acidosis due to absolute or relative 
deficiency, and insulin resistance, thereby leading to vascular complications such as 
retinopathy, neuropathy, and nephropathy. This study evaluated the levels of plasma 
bilirubin, ALP, and GGT among diabetic patients. A total of eighty (80) individuals were 
recruited for the study comprising of forty (40) diabetes patients with age range 25-80 
years and forty (40) control subjects with the age range of 20-30 years in 
Irrua/Ekpoma, Edo State, Nigeria. The study was carried out within six months 
(December 2018 - May 2019). All patients were diabetes. The serum Alkaline 
Phosphatase (ALP), gamma-glutamyl transferase (GGT), total and conjugated 
bilirubin were assayed by spectrophotometric method, and the data obtained were 
statistically analyzed using SPSS version 23.0 software. Serum levels of ALP, GGT, 
Total and unconjugated bilirubin were significantly elevated (P<0.05) among diabetes 
patients than control subjects except for conjugated bilirubin which was lower (P>0.05)  
when compared with that of the control subjects. The mean serum levels of  ALP, 
GGT, total, unconjugated and conjugated bilirubin of male diabetes patients were non 
statistically significant (P>0.05) when compared with female diabetes subjects except 
the age (P<0.05). These findings indicate that hepatic injury was more likely among 
diabetes, and liver enzymes (ALP, GGT) are critical for monitoring glucose control 
concomitant with hepatic injury. Bilirubin is a potentially important biomarker for the 
assessment of the hepatic excretory system in diabetes mellitus. 
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INTRODUCTION 
 Diabetes mellitus is a metabolic disorder characterized by chronic 
hyperglycemia glycosuria, increased protein breakdown, ketosis, or acidosis, resulting 
from defective insulin action and secretion, leading to vascular complications such as 
retinopathy, neuropathy, and nephropathy (WHO, 1999). The role of the liver in DM 
has been long recognized because of its important place in carbohydrate metabolism. 
The loss of insulin effect on the liver leads to glycogenolysis and an increase in hepatic 
glucose production. World Health Organization projects that diabetic patients will 
exceed 350 million by 2030 (WHO, F1999). The prevalence value has not been 
uniform in Nigeria, though the International diabetic federation recorded 3.9% in its 
current Atlas.  
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         Previous data have documented liver disease is a significant cause of morbidity 
and mortality of type 2 diabetes patients (Al-Jameil et al., 2014., Hanley et al., 2004). 
It is well known that the liver is a vital organ in the metabolism of carbohydrates and 
in maintaining glucose homeostasis during fasting and postprandial period ((Al-
Jameil et al., 2014., Gavin, 1999). 
         Diabetic Mellitus (DM) leads to change in the liver-related to both function and 
morphology. ALP metabolizes phosphorus to bring energy to the body. In contrast, 
GGT brings energy to the tissues and enhances the metabolism of glutathione, the 
main thiol intracellular antioxidant agent in mammalian cells (Whitfield, 2001). Bilirubin 
is a yellow breakdown product of heme metabolism whose importance is antioxidant, 
removing peroxyl radicals generated by oxidative stress, which is associated with 
hyperglycemia state (Ndisang, 2009), thereby preventing diabetic vascular 
complications. Non-alcoholic fatty liver disease (NAFLD) is the scope of chronic liver 
disease in type 2 diabetes patients (Ballestri et al., 2016), which is characterized by 
excess deposition of fat in the liver and is associated with hepatic insulin resistance 
(Hanley et al.,2004) and type 2 Diabetes patients risk (Ballestri et al., 2016). Serum 
alkaline phosphatase (ALP),gamma-glutamyltransferase (GGT), and alanine 
aminotransferases (ALT) are suitable biomarkers of NAFLD. ALT and bilirubin have 
been considered the specific marker of liver injury, as found in high hepatocyte 
concentrations (Gianni, 2005), while GGT is present on the surface of most cell types 
and highly active in the liver, kidneys, and pancreas (Hanigan, 1996). Also, GGT is 
responsible for extracellular glutathione catabolism and may be linked to oxidative 
stress (Turgut, 2011) and chronic inflammation (Lee, 2004); both oxidative stress and 
chronic inflammation are essential pathways for hepatic insulin resistance (IR) and 
subsequently T2D development (Wang, 2016).    
         Previous data justified that diabetes causes hepatic injury such as hepatomegaly 
which in type I is related to an increase in the glycogen content. In contrast, type II is 
associated with fatty change, thereby leading to cytolysis and leakage out of the 
necrotic and damaged liver cells. Further data also reveals that the elevation of liver 
enzymes could express excess fat deposition in the liver, which is regarded as a 
feature of the insulin resistance syndrome (Chen,2008., Hammerman et al.,1998). 
There is clear evidence that cellular GGT level is closely related to oxidative stress 
indicators in vivo, either as an antioxidant or a pro-oxidant, depending on the 
circumstance (Schwertner,1994). It has been reported that many diabetes patients 
exhibit elevated levels of ALP, enzymes of the liver (ALT, AST, and GGT).  
         However, few studies reported that hepatic enzymes (ALP and GGT) are critical 
enzymes in monitoring diabetic Mellitus concomitant with liver injury and bilirubin are 
potentially essential biomarkers for assessing the hepatic excretory system in diabetes 
mellitus. Research is the first study carried out on diabetes patients in Esan people of 
Edo State, Nigeria. Hence, this case-control study was conducted to assess the effect 
of diabetes on the excretory function of the liver in a sample of Esan patients with 
diabetes mellitus. 
 
MATERIALS AND METHODS 
Study Design and Population 
 The study was carried out at Irrua, Esan Central Local Government and 
Ekpoma, Esan- West Local Government Area of Edo State, Nigeria. Irrua is a rural 
area located at latitude 6.7 N and longitude 6.2 E, with 105310 people. The people are 
farmers, traders, and Civil service workers. Ekpoma is a rural area located at latitude 
6.5 Nand longitude 6.0 E, with 125842 people. The people are mainly farmers, traders, 
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and civil service workers. A total of 80 subjects (male and female) comprised 40 
diagnosed patients with diabetes mellitus and 40 healthy subjects as control. The 
patients were sampled at Irrua specialist teaching hospital, Irrua, while the healthy 
subjects mainly were students of AAU, Ekpoma. The study populations were divided 
into two groups, A and B.Group A included 40 subjects with diabetes mellitus, while 
Group B had 40 healthy subjects as control. 
         The research was designed to evaluate the serum levels of ALP, gamma-
glutamyl transferases (GGT) level, ALT, AST, and bilirubin (Total and indirect) in 
patients with diabetes mellitus with levels of the control subjects. The study was 
carried out within six (6) months (December 2018 – May 2019). Samples were 
collected twice-weekly (Mondays, Wednesdays). The patient's clinical diagnosis was 
confirmed by determining fasting blood sugar (FBS), which was above 126 mg/dl. (7.0 
mmol/l) while that of the apparently healthy subjects was confirmed by determination 
of fasting blood sugar (FBS), which was below 110 mg/dl (6.1mmol/l). 
Ethical consideration 
         Ethical clearance was obtained from Edo State Ministry of Health, Benin City, 
Nigeria (ethical code 1208/157, dated 8th June 2018). Permission was obtained from 
the head of the department (Chemical pathology option), and informed consent was 
obtained from individual subjects before the commencement of the study. 
Inclusion and exclusion criteria 
         Patients with diabetes mellitus were included while patients suffering from a 
hepatic disorder, alcoholic patients, pregnancy or use of oral contraceptives (in case 
of female subjects), and those using abused substances like hard drugs(barbiturate) 
that affects liver enzymes were excluded from the study. 
Measurement of ALP, GGT, and Bilirubin  
         The Plasma Alkaline Phosphatase (ALP), gamma-glutamyl transferase (GGT) 
were measured enzymatically, total and conjugated bilirubin was measured by 
Jendrassik and Grof's method using V-730 UV-visible spectrophotometer (Easton, MD 
21601, USA)  
Statistical Analysis 
         Results obtained are presented as mean ± standard deviation (SD). Data 
obtained were statistically analyzed using IBM SPSS Statistics version 23.0 software. 
The comparison of the mean values of measured parameters among diabetes 
subjects and control was performed using the Student t-test, the result obtained was 
compared at 95% confidence level (p<0.05-significance) 
 
RESULTS AND DISCUSSION 
The study was performed on eighty (80) subjects; subjects were divided into 
groups A and B. group A included forty (40) diabetes mellitus subjects, and Group B 
included forty (40) apparently healthy subjects. The results of the study are shown 
below. Table1 shows the comparison serum ALP, GGT, and bilirubin (total, conjugated 
and unconjugated) among diabetes and control subjects. It was observed that plasma 
ALP, GGT, total bilirubin, and unconjugated bilirubin were significantly elevated in 
diabetes mellitus than in control subjects (P<0.05), While plasma conjugated bilirubin 
was lower in diabetes mellitus than control subjects (P>0.05).  
         Table 2 compares the biochemical parameters (ALP, GGT, total bilirubin, 
conjugated, unconjugated bilirubin, and fasting blood sugar) among male and female 
diabetes and its control. It was observed that there were non statistically significant in 
the biochemical parameter (P>0.05) 
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Table 1 . Comparison of ALP, GGT, Total Bilirubin, Unconjugated and Conjugated 








ALP(U/L) 183.83±11.68 119.60±6.64 P<0.05** 
GGT(U/L) 26.85±10.96 11.20±4.85 P<0.05** 
TB(mg/dl) 1.29±0.58 1.00±0.59 P<0.05** 
UCB(mg/dl) 0.99±0.56 0.63±0.51 P<0.05** 
CB(mg/dl) 0.29±0.19 0.37±0.28 P>0.05* 
Values are expressed in mean±SD. **P<0.05 Significant, *P>0.05 Non 
significant ALP-Alkalinephosphatase, GGT-Gamma-glutamyl 
transferase, TB-Total bilirubin, UCB-Unconjugated bilirubin, CB-
Conjugated bilirubin. 
 
Table 2. Comparison of ALP, GGT, Total Bilirubin, Unconjugated and Conjugated 
Bilirubin between Male and Female Subjects 







ALP(U/L) 170.64±3,73 188.83±13.54 P>0.05* 
GGT(U/L) 29.76±1.44 25.35±9.36 P>0.05* 
TB(mg/dl) 1.33±0.68 1.27±0.55 P>0.05* 
UCB(mg/dl) 0.99±0.65 0.99±0.53 P>0.05* 
CB(mg/dl) 0.33±0.21 0.27±0.18 P>0.05* 
FBS(mg/dl) 188.64±7.49 192±7.9 P>0.05* 
Values are expressed in mean±SD.** P<0.05 Significant, *P>0.05 Non 
significant ALP-Alkalinephosphatase, GGT-Gamma-glutamyl 
transferase, TB-Total bilirubin, UCB-Unconjugated bilirubin, CB-
Conjugated bilirubin, FBS-Fasting blood sugar. 
 
 Diabetes mellitus (DM) is a fundamental health challenge and one of the 
primary causes of death worldwide; more than half of diabetes remains undiagnosed, 
primarily type 2. The cause of this is insulin deficiency or relative insensitivity of insulin 
receptors. Without a timely diagnosis, the complication continues to be on the rise. 
According to WHO, 70% of diabetes reside in developing countries, to which Nigeria 
belongs. This research determined to evaluate the excretory function of the liver by 
assessing the liver enzymes(ALP, GGT) and bilirubin among diabetic subjects.  
         This study made statistical comparisons of plasma ALP, GGT, and bilirubin 
(Total, unconjugated and conjugated) for diabetes and apparently healthy control 
subjects. It was observed that the level of plasma ALP, GGT, total bilirubin, and 
unconjugated bilirubin were significantly increased with a p-value less than 0.05 
(P<0.05) while conjugated bilirubin was significantly decreased with a p-value greater 
than 0.05 (P>0.05) (Table1). 
         The significantly increased level of ALP as observed in diabetic Mellitus could 
be a result of the increased call for energy through ALP activity rather than the 
glycolytic and oxidative pathway of glucose six phosphates. Also, insulin deficiency or 
insulin resistance in DM reduced lipoprotein lipase activity and hepatic lipase 
responsible for the catabolism of lipoprotein (VLDL and chylomicron) and TG on HDL, 
thereby resulting from decreasing the clearance of remnant lipoprotein and 
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accumulation of VLDL. The impaired ability of insulin to inhibit free fatty acid (FFA) 
release leads to enhance hepatic VLDL cholesterol production, which correlates with 
the degree of hepatic fat accumulation (Schielman,1975). The increased cholesterol 
content of the bile and increased gallbladder volume create a “primed environment for 
stone formation in the biliary tract that could result in partial or complete obstruction 
(Cholestasis) attributed to cytolysis and leakage out of the necrotic and damaged cell 
of the liver. It might also be attributed to the proliferation of the bile duct in the absence 
of obstruction, as seen in a diabetic cirrhotic patient. 
         This study was consistent with the result in (Falchuk 1993., Ginsberg, 1996., 
Sherlock,1985). They believed that diabetes causes hepatic injury such as 
hepatomegaly which in type I is related to an increase in the glycogen content. In 
contrast, type II is associated with fatty change, thereby leading to cytolysis and 
leakage out of the necrotic and damaged liver cells in diabetes mellitus. 
         In this study, plasma GGT level in diabetes patients was elevated compared with 
a control group, and the difference was highly significant (P<0.05) statistically. The 
increase of GGT in diabetes mellitus could result from intrahepatic inflammation, an 
early marker of oxidation stress (Monami et al.,2008). One explanation for this 
observation is that the elevation of liver enzymes could express excess fat deposition 
in the liver, regarded as a feature of the insulin resistance syndrome (Marchesini et 
al.,2001., Malnick, 2003). There is clear evidence that cellular GGT level is closely 
related to oxidative stress indicators in vivo, either as an antioxidant or a pro-oxidant, 
depending on circumstance. (Hsueh,2003).  
         An increase in plasma GGT activity may respond to oxidative stress, making 
increased glutathione transport into cells, supporting a role of plasma GGT in the 
inflammation and oxidative stress. Another explanation might be related to liver 
response to pro-inflammatory cytokine TNF giving fatty hepatic change or the 
inflammatory processes accompanying non-alcoholic fatty liver and contributing to the 
systemic inflammation observed in these subjects frequently affected with metabolic 
syndrome (Perlstein et al., 2008). It might also be attributed to cholestasis (partial or 
complete blockage of the bile duct), resulting in cytolysis and leakage of necrotic and 
damaged liver cells. This study was consistent with the result in (Falchuk,1993., 
Ginsberg,1996., Lee et al.,2003., Monami et al.,2008., Sherlock,1985), they reported 
that the elevation of the hepatic enzyme (GGT) could be an expression of excess 
deposition of fat in the liver (intrahepatic inflammation) and oxidation stress associated 
with Diabetes Mellitus which therefore increase the metabolism of glutathione, a 
critical antioxidant defense thereby increasing the transport into the cell. They were 
also opinion that cytolysis and leakage out of necrotic and damaged liver cells in 
diabetes mellitus might be attributed to increasing plasma GGT. 
         In this study, Plasma total bilirubin in DM patients was elevated compared with 
a control group, and the difference was highly significant (p<0.05) statistically. The 
increase of plasma total bilirubin in DM could result from an increased level of peroxyl 
radicals generated by oxidative stress, which is associated with the hyperglycaemic 
state. (Ndisang, 2009). Increase total bilirubin seen in this study is protective against 
coronary artery, stroke, and peripheral vascular diseases associated with metabolic 
syndromes and diabetes mellitus (Kern et al.,1973). Bilirubin has been regarded as a 
powerful endogenous antioxidant and anti-inflammatory agent (Chen, 2008., 
Stocker et al.,1987); thus, it stands to reason that increased total bilirubin level may 
be protective against autoimmune inflammation-related pathology of types I DM and 
oxidative physiologic stress associated with the development of type 2 DM. 
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         Current research also suggests that an increased level of total bilirubin block the 
product of various free radicals that might hinder the inhibitory response of the cell to 
take up the high glucose (Hammerman et al., 1998). This study was consistent with 
the result of a previous study (Lin et al., 2006., Perlstein et al.,2008., 
Schwertner,1994). They reported that an increased level of total plasma bilirubin is 
protective against peripheral vascular complications (Neuropathy, Nephropathy, and 
retinopathy) associated with oxidative stress in type II diabetes, thereby reducing the 
odds of incidence and prevalence of diabetes mellitus. This study shows that 
unconjugated bilirubin conveys the antioxidant effect, which protects against vascular 
complications. Also, there appears to be a beneficial effect of total bilirubin on 
diabetes. 
         In this study, plasma conjugated bilirubin in diabetes patients was lower when 
compared with a control group, and the difference was non statistically significant 
(P>0.05). The decreased level of serum conjugated bilirubin in DM might be attributed 
to the problem of upstream excretion of bilirubin which reflects liver cell damage or bile 
duct damage within the liver itself, in which hemolysis, viral hepatitis, or cirrhosis can 
be suspected. Also, in the later stage of cholestasis, conjugated bilirubin may be 
elevated due to liver damage as a secondary effect of cholestasis. 
         Therefore, the hepatic fat accumulation may progress to fibrosis and cirrhosis, 
the most common clinical presentation is hepatomegaly, and diabetic patients have 
abnormal liver enzymes (ALP, GGT, transaminases) and normal conjugated bilirubin 
(Kern et al., 1973., Marchesini et al.,2001., Zimmerman et al., 1950). The mechanism 
of low/normal conjugated bilirubin is unclear but is perhaps related to diabetes cirrhotic 
condition. 
 From this study. It was also observed that the level of fasting blood sugar and 
ALP in diabetes females and males was not statistically significant, despite a slight 
rise in FBS and ALP in females than the male, which could be attributed to the effect 
of menopause and age. Previous studies reported by Ali (Ali, 2005., Ali, 2006) shows 
that elevated ALP in females diabetes was due to an increase of cholesterol content, 
high level of fat adiposity, and insulin deficiency (Ali, 2006., Martin, 2006) which is in 
agreement with this study. The presence of ALP in human pre-adipocytes is of interest 
that adipose tissue might be a source of serum ALP. Previous studies by Bin et 
al. (2021) reported a positive relationship between dyslipidemia and liver enzymes in 
diabetes; adipose tissue mass can influence the release of liver product into the 
circulation (increase ALP).  
         It was observed that the total serum bilirubin in male diabetes and female 
diabetes subjects were not statistically significant despite there being a rise in total 
bilirubin in male diabetes. A previous study done by Martin reported that it might be 
due to cardiovascular disease (coronary heart disease and myocardial infarction), 
which is commoner in males resulting from abnormal lipid (high plasma cholesterol 
and triglycerides and low high-density lipoprotein (HDL) among diabetes mellitus 
(Martin, 2006). Previous studies reported that the Increase concentration of serum 
bilirubin is in line with our finding In that it has an antioxidant effect on coronary artery 
disease (Breimer,1995., Hopkin et al.,1996., Schwertner,1994), stroke (Chen, 2008), 
and diabetic vascular complication (Inogochi et al.,2007).  
 The present study assesses the level of ALP as a biomarker of the excretion 
function of the liver. However, there are some limitations. First, our sample size may 
be small. Second, we measured the ALP and GGT once, which may not represent a 
long-term profile. Thus, further large sample sizes and repeat measurements of ALP 
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Serum levels of ALP, GGT, total and unconjugated bilirubin were elevated, and 
low conjugated bilirubin was observed among diabetic subjects. This result shows that 
hepatic injury was more likely among diabetes patients. It is therefore suggested that 
hepatic enzymes (ALP and GGT) are critical enzymes in monitoring diabetes mellitus 
concomitant with liver injury and bilirubin are potentially essential biomarkers for the 
assessment of the hepatic excretory system in diabetes mellitus. 
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